HMM: Moderna Shares Double on Success of mRNA Cancer Vaccine.
An experimental mRNA-based vaccine succeeded in preventing cancer from coming back or spreading in a study of high-risk melanoma patients, Moderna and its partner Merck said Wednesday, paving the way for a potentially new life-extending treatment for the thousands of people diagnosed with the deadly skin cancer each year.
…
The study looked at people who had surgery to remove a melanoma—the point of the treatment was to reduce the risk of it coming back.The companies said the late-stage study, which tested the personalized cancer vaccine intismeran in combination with Merck’s blockbuster cancer immunotherapy Keytruda, met its main goal of extending the time before cancer returns in high-risk patients. The study also met a secondary goal of preventing the disease from spreading to different organs.
“I have a feeling that this is just the beginning of a new field,” said Jane Healy, a vice president of oncology at Merck, adding the goal for patients is “to give them longer without having to worry about treatments for cancer.”
Developing…